Clinical Trials Logo

Clinical Trial Summary

The study is a domestic multicenter, prospective, non-randomized controlled concurrent trial. It will be assessed whether surgery staging on locally advanced cervical cancer is superior to image staging for improving progression-free survival and overall survival.


Clinical Trial Description

All eligible patients will be divided into the following two treatment groups nonrandomly. Image staging group: standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+brachytherapy). Surgery staging group: open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (Level of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation will be conducted within 28 days postoperatively.) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05378087
Study type Interventional
Source Chongqing University Cancer Hospital
Contact Dongling Zou, M.D.
Phone 13657690699
Email cqzl_zdl@163.com
Status Recruiting
Phase N/A
Start date June 27, 2022
Completion date December 31, 2032

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT06079671 - Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3
Completed NCT05059119 - Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
Recruiting NCT06055738 - Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC Phase 2
Recruiting NCT06156514 - Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer Phase 3
Completed NCT03298893 - Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months Phase 1/Phase 2
Withdrawn NCT01514955 - An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer Phase 1
Recruiting NCT05950087 - Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Recruiting NCT04884906 - Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer Phase 2
Not yet recruiting NCT05799469 - Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Terminated NCT02045433 - Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT06237257 - A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT06288360 - Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Phase 2
Not yet recruiting NCT06288373 - Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Phase 2/Phase 3
Recruiting NCT06068387 - A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis N/A
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2
Recruiting NCT01938105 - Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer Phase 2
Active, not recruiting NCT01793701 - Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2
Completed NCT01230996 - Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2